Keytruda and PD-(L)1 LoE: Life after Programmed Death (part 1)
In the first of a new series of CRA Insights on this topic, Aaron Everitt looks at how Keytruda and other branded and biosimilar manufacturers are preparing...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Mr. Aaron Everitt is a principal in the Life Sciences Practice of CRA. He has over five years of consulting experience in Pricing & Market Access, across the EU and US, with experience in LATAM, APAC and MEA. Dr. Everitt has a PhD background in immunology and virology.